Literature DB >> 9854598

Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome.

H R Alexander1, D L Bartlett, D J Venzon, S K Libutti, J L Doppman, D L Fraker, J A Norton, F Gibril, R T Jensen.   

Abstract

BACKGROUND: Only 30% to 40% of patients with Zollinger-Ellison syndrome (ZES) undergoing operation with curative intent have biochemical cures. The purpose of this analysis was to identify perioperative factors associated with long-term (> or = 5 years) biochemical cures.
METHODS: From December 1981 to September 1997, 128 patients with potentially curable ZES underwent 152 abdominal explorations with resection of all identifiable disease. Of these, 31 outcomes were identified with documented cures at > or = 5 years from operation and were compared with outcomes of 110 patients who were not cured. Univariate and multivariate statistical analyses were performed.
RESULTS: The results of a normal immediate postoperative fasting serum gastrin and secretin stimulation test were significantly and independently correlated with 5-year cure (P2 = .005 and .0099, respectively). A diagnosis of multiple endocrine neoplasia type 1 was significantly inversely correlated with cure on univariate analysis (P2 = .027). Gender, age, duration of symptoms, results of diagnostic tests, or results of imaging studies did not correlate with outcome.
CONCLUSIONS: All patients with sporadic potentially curable ZES should undergo exploration because outcome is not associated with preoperative tests. Only 5% of patients with ZES and multiple endocrine neoplasia type 1 were cured at 5 years. A normal fasting serum gastrin or secretin stimulation value value immediately postoperatively provides important prognostic information.

Entities:  

Mesh:

Year:  1998        PMID: 9854598     DOI: 10.1067/msy.1998.92010

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  4 in total

1.  Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients.

Authors:  Masayuki Imamura; Izumi Komoto; Shuichi Ota; Takuya Hiratsuka; Shinji Kosugi; Ryuichiro Doi; Masaaki Awane; Naoya Inoue
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

2.  Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.

Authors:  Jeffrey A Norton; David J Venzon; Marc J Berna; H R Alexander; Douglas L Fraker; Stephen K Libutti; Stephen J Marx; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

3.  Insulinoma and gastrinoma syndromes from a single intrapancreatic neuroendocrine tumor.

Authors:  Maya B Lodish; Anathea C Powell; Mones Abu-Asab; Craig Cochran; Petra Lenz; Steven K Libutti; James F Pingpank; Maria Tsokos; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2008-02-05       Impact factor: 5.958

Review 4.  Gastrinoma.

Authors:  M L Li; J A Norton
Journal:  Curr Treat Options Oncol       Date:  2001-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.